← board
RANI
distress 4/10 · elevated risk$0.88-2%today-69% from 52w high
Revenue
pre-revenue
Liquidity
$108M
Runway
6.3 yrs
Shares 1y
—
Price & events
-37.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.5%
1D
+30.6%
1W
+15.9%
1M
-4.5%
3M
-37.1%
6M
+92.3%
1Y
-71.1%
2Y
—
5Y
-92.0%
All
Overview
- Volume
- 359.72K
- 52 Week Range
- $0.41 – $2.85
- Float Shares
- 69.02M
- Short %
- 8.30%
- % Held by Insiders
- 4.99%
- % Held by Institutions
- 43.90%
- RVOL
- 0.42x
- Beta
- 0.80
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+757% upside) · 4 analysts
- 2026-05-20Canaccord GenuityBuy
- 2026-04-01Canaccord GenuityBuy
- 2026-03-27HC Wainwright & Co.Buy
- 2026-01-09HC Wainwright & Co.Buy
- 2025-10-20Maxim GroupBuy
- 2025-05-16OppenheimerOutperform
Competitors
- none identified
Recent news
- 2026-07-22Rani Therapeutics Holdings (NASDAQ:RANI) surges 29%, shrinking Nasdaq compliance deficit to 11% - TechStock²
- 2026-07-22Form 4 Rani Therapeutics Holdings Inc For: 22 July By Investing.com - Investing.com Nigeria
- 2026-07-21Form 4 Rani Therapeutics Holdings Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Rani Therapeutics (RANI) CTO records stock sale and tax withholding - Stock Titan
- 2026-07-21Rani Therapeutics CEO Talat Imran buys $25,193 in stock - Investing.com
- 2026-07-21Rani Therapeutics (RANI) CEO purchases 35,000 shares in open-market trade - Stock Titan
- 2026-07-21Rani Therapeutics (RANI) CEO logs RSU-related tax share sales - Stock Titan
- 2026-07-21Rani Therapeutics (RANI) grants 2M stock options to its CFO - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.